Study of Patients with Neuroendocrine Tumours using NCRAS data
Research type
Research Study
Full title
Real World Evidence Study of Treatment Patterns and Healthcare Resource Utilisation in Patients with Neuroendocrine Tumours (NETs)
IRAS ID
313231
Contact name
Artak Khachatryan
Contact email
Sponsor organisation
LA-SER EUROPE LIMITED (a Certara company)
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
This study seeks to describe NET patients from England (population 54 million) which will permit the identification of large, representative samples of NET patients, which in turn will yield findings with high external validity. This country has also experienced the introduction and utilization of the latest approved treatments for NET while having a rich historical background of using many other treatments against these tumours, including somatostatins analogues, resections, radiotherapies, and chemotherapies.
This study will therefore provide much needed description of the NET populations, especially pNET and epNET. NCRAS is a rich set of datasets covering nationwide cancer registrations and antineoplastic care delivered. Through linkages, other data sources of healthcare utilisation (inpatient, outpatient, and A&E services) will be investigated and described. This will also allow contemporary cost of NET care to be estimated. It is a rich source of clinical and health administrative data, including diagnoses, treatment delivered healthcare resource utilisation (inpatient and outpatients) and their costs. This data source will also be employed to provide a description of the recent NET treatment landscape.REC name
South Central - Oxford C Research Ethics Committee
REC reference
22/SC/0345
Date of REC Opinion
30 Aug 2022
REC opinion
Favourable Opinion